Cargando…

Left Ventricular Flow Distribution as a Novel Flow Biomarker in Atrial Fibrillation

Introduction: Four-dimensional (4-D) flow cardiac magnetic resonance imaging can be used to elegantly describe the hemodynamic efficiency of left ventricular (LV) flow throughout the cardiac cycle. Patients with nonvalvular paroxysmal atrial fibrillation (PAF) may have occult LV disease. Flow distri...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Hansuk, Sheitt, Hana, Wilton, Stephen B., White, James A., Garcia, Julio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8657405/
https://www.ncbi.nlm.nih.gov/pubmed/34900953
http://dx.doi.org/10.3389/fbioe.2021.725121
_version_ 1784612495522004992
author Kim, Hansuk
Sheitt, Hana
Wilton, Stephen B.
White, James A.
Garcia, Julio
author_facet Kim, Hansuk
Sheitt, Hana
Wilton, Stephen B.
White, James A.
Garcia, Julio
author_sort Kim, Hansuk
collection PubMed
description Introduction: Four-dimensional (4-D) flow cardiac magnetic resonance imaging can be used to elegantly describe the hemodynamic efficiency of left ventricular (LV) flow throughout the cardiac cycle. Patients with nonvalvular paroxysmal atrial fibrillation (PAF) may have occult LV disease. Flow distribution analysis, based on 4-D flow, may unmask the presence of LV disease by assessing flow components: direct flow, retained flow, delayed ejection, and residual volume. This study aimed to identify LV hemodynamic inefficiencies in patients with PAF and normal systolic function. We hypothesized that the fraction of direct flow to the total end-diastolic volume would be reduced in patients with PAF compared with controls. Methods: We used 4-D LV flow component analysis to compare hemodynamics in 30 healthy controls and 50 PAF patients in sinus rhythm. Results: PAF subjects and healthy controls had similar LV mass, volume, and ejection fraction. Direct flow was lower in the PAF group than in the controls (44.5 ± 11.2% vs. 50.0 ± 12.2%, p = 0.042) while delayed ejection was higher in the PAF group (21.6 ± 5.6% vs. 18.6 ± 5.7%, p = 0.022). Conclusion: PAF patients demonstrated a relative reduction in direct flow and elevation in delayed ejection.
format Online
Article
Text
id pubmed-8657405
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-86574052021-12-10 Left Ventricular Flow Distribution as a Novel Flow Biomarker in Atrial Fibrillation Kim, Hansuk Sheitt, Hana Wilton, Stephen B. White, James A. Garcia, Julio Front Bioeng Biotechnol Bioengineering and Biotechnology Introduction: Four-dimensional (4-D) flow cardiac magnetic resonance imaging can be used to elegantly describe the hemodynamic efficiency of left ventricular (LV) flow throughout the cardiac cycle. Patients with nonvalvular paroxysmal atrial fibrillation (PAF) may have occult LV disease. Flow distribution analysis, based on 4-D flow, may unmask the presence of LV disease by assessing flow components: direct flow, retained flow, delayed ejection, and residual volume. This study aimed to identify LV hemodynamic inefficiencies in patients with PAF and normal systolic function. We hypothesized that the fraction of direct flow to the total end-diastolic volume would be reduced in patients with PAF compared with controls. Methods: We used 4-D LV flow component analysis to compare hemodynamics in 30 healthy controls and 50 PAF patients in sinus rhythm. Results: PAF subjects and healthy controls had similar LV mass, volume, and ejection fraction. Direct flow was lower in the PAF group than in the controls (44.5 ± 11.2% vs. 50.0 ± 12.2%, p = 0.042) while delayed ejection was higher in the PAF group (21.6 ± 5.6% vs. 18.6 ± 5.7%, p = 0.022). Conclusion: PAF patients demonstrated a relative reduction in direct flow and elevation in delayed ejection. Frontiers Media S.A. 2021-11-25 /pmc/articles/PMC8657405/ /pubmed/34900953 http://dx.doi.org/10.3389/fbioe.2021.725121 Text en Copyright © 2021 Kim, Sheitt, Wilton, White and Garcia. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Bioengineering and Biotechnology
Kim, Hansuk
Sheitt, Hana
Wilton, Stephen B.
White, James A.
Garcia, Julio
Left Ventricular Flow Distribution as a Novel Flow Biomarker in Atrial Fibrillation
title Left Ventricular Flow Distribution as a Novel Flow Biomarker in Atrial Fibrillation
title_full Left Ventricular Flow Distribution as a Novel Flow Biomarker in Atrial Fibrillation
title_fullStr Left Ventricular Flow Distribution as a Novel Flow Biomarker in Atrial Fibrillation
title_full_unstemmed Left Ventricular Flow Distribution as a Novel Flow Biomarker in Atrial Fibrillation
title_short Left Ventricular Flow Distribution as a Novel Flow Biomarker in Atrial Fibrillation
title_sort left ventricular flow distribution as a novel flow biomarker in atrial fibrillation
topic Bioengineering and Biotechnology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8657405/
https://www.ncbi.nlm.nih.gov/pubmed/34900953
http://dx.doi.org/10.3389/fbioe.2021.725121
work_keys_str_mv AT kimhansuk leftventricularflowdistributionasanovelflowbiomarkerinatrialfibrillation
AT sheitthana leftventricularflowdistributionasanovelflowbiomarkerinatrialfibrillation
AT wiltonstephenb leftventricularflowdistributionasanovelflowbiomarkerinatrialfibrillation
AT whitejamesa leftventricularflowdistributionasanovelflowbiomarkerinatrialfibrillation
AT garciajulio leftventricularflowdistributionasanovelflowbiomarkerinatrialfibrillation